Euglycaemic diabetic ketoacidosis in patients using sodium‐glucose co‐transporter 2 inhibitors

Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) are an increasingly prescribed class of medication for type 2 diabetes mellitus. Euglycaemic diabetic ketoacidosis (euDKA) has been reported in association with SGLT2i use. Clinicians need to understand how to recognise and treat this complication....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Internal medicine journal 2017-06, Vol.47 (6), p.701-704
Hauptverfasser:	Isaacs, Michelle, Tonks, Katherine T., Greenfield, Jerry R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged, 80 and over Benzhydryl Compounds - adverse effects Diabetes Diabetes mellitus diabetes mellitus, type 2 Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy diabetic ketoacidosis Diabetic Ketoacidosis - blood Diabetic Ketoacidosis - chemically induced Diabetic Ketoacidosis - diagnosis Female Glucose transporter Glucosides - adverse effects Humans hypoglycaemic agents Ketoacidosis Male Middle Aged Sodium Sodium-Glucose Transporter 2 Sodium-Glucose Transporter 2 Inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) are an increasingly prescribed class of medication for type 2 diabetes mellitus. Euglycaemic diabetic ketoacidosis (euDKA) has been reported in association with SGLT2i use. Clinicians need to understand how to recognise and treat this complication. We describe three cases of euDKA in patients treated with SGLT2i.
ISSN:	1444-0903 1445-5994
DOI:	10.1111/imj.13442